SeekingAlpha · Aug 25, 2026
Omnicell: Offers Good Value, But Uncertainty Remains
Omnicell, Inc. is rated a Hold; it faces near-term headwinds, with YoY revenue contraction, for the first time in seven quarters. Read more on OMCL stock here.
NYSE · BDX
Becton, Dickinson and Company
Healthcare · Medical - Instruments & Supplies
$189.52
Up+$1.39 (+0.74%)
Updated Aug 31, 2026, 8:28 AM
SID Score
6.2/10
Composite research score
Smart Money
47/100
Neutral
- Market cap
- 57.44B
- P/E ratio
- 34.23
- Dividend yield
- 2.20%
- 52-week range
- $140.11 – $213.08
- Volume
- 1.69M
- Avg. volume
- 1.98M
Price performance
BDX price history
1M range · 20 trading sessions · Daily adjusted prices
BDX closed at $189.52 after 20 trading sessions, up 11.34% for the selected period.
- Last close
- $189.52
- Period change
- +11.34%
- Period low
- $170.12
- Period high
- $192.00
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $188.04 | $190.32 | $187.5375 | $189.52 | 1.69M |
| Aug 27, 2026 | $189.29 | $190.41 | $187.73 | $188.13 | 1.35M |
| Aug 26, 2026 | $188.49 | $191.52 | $188.02 | $190.21 | 1.4M |
| Aug 25, 2026 | $189.31 | $190.07 | $187.03 | $189.78 | 1.21M |
| Aug 24, 2026 | $191.73 | $193.07 | $190.35 | $190.74 | 1.31M |
| Aug 21, 2026 | $188.02 | $192.295 | $186.95 | $192.00 | 2.52M |
| Aug 20, 2026 | $186.20 | $190.01 | $185.36 | $187.62 | 1.97M |
| Aug 19, 2026 | $183.71 | $187.96 | $181.5158 | $187.60 | 2.16M |
| Aug 18, 2026 | $184.94 | $185.80 | $180.72 | $180.77 | 1.62M |
| Aug 17, 2026 | $181.89 | $183.46 | $181.62 | $182.09 | 1.31M |
| Aug 14, 2026 | $182.12 | $183.82 | $181.22 | $183.40 | 1.01M |
| Aug 13, 2026 | $184.75 | $185.32 | $181.41 | $181.97 | 2.16M |
| Aug 12, 2026 | $177.61 | $183.75 | $177.13 | $183.58 | 1.55M |
| Aug 11, 2026 | $178.35 | $181.79 | $178.35 | $181.41 | 1.52M |
| Aug 10, 2026 | $176.49 | $179.79 | $175.63 | $179.63 | 1.77M |
| Aug 7, 2026 | $175.26 | $177.545 | $173.2937 | $176.86 | 1.85M |
| Aug 6, 2026 | $175.88 | $179.40 | $172.76 | $177.07 | 3.3M |
| Aug 5, 2026 | $169.73 | $170.91 | $168.01 | $170.66 | 2.54M |
| Aug 4, 2026 | $168.00 | $170.76 | $166.80 | $170.12 | 2.1M |
| Aug 3, 2026 | $167.75 | $171.21 | $167.155 | $170.21 | 1.73M |
Latest BDX news
The latest Smart Investors Daily articles mentioning BDX.
Stock researchCompany · Overview
BDX research
Overview
Company profile and research snapshot.
Company profile
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $210.00
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | RBC Capital | Sector Perform | — |
| Aug 7, 2026 | Piper Sandler | Neutral | — |
| Aug 7, 2026 | RBC Capital | Sector Perform | — |
| Aug 7, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 7, 2026 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 22, 2026
Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends
Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...
Yahoo · Aug 21, 2026
Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks
Becton Dickinson stock has delivered a 25.4% return over the past year, while current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. Over the last 12 months, Becton Dickinson has returned 25.4%, which puts recent gains in focus when assessing how much upside may remain. Progress on the PREVENT clinical trial can support long term cash flow expectations, while the recent recall of...
Yahoo · Aug 21, 2026
Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh
Becton Dickinson (NYSE:BDX) reported completion of patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for prevention of incisional hernias. The large scale study is designed to assess the safety and effectiveness of Phasix Mesh as a prophylactic option in patients undergoing abdominal surgery. Finishing enrollment moves the trial closer to data readout and potential regulatory review for what the company positions as a first of its kind product in this category. The...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
